Shanghai Fosun Pharmaceutical (Group) Management
Management criteria checks 2/4
Shanghai Fosun Pharmaceutical (Group)'s CEO is Deyong Wen, appointed in Jan 2022, has a tenure of 2.83 years. total yearly compensation is CN¥10.00M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.004% of the company’s shares, worth CN¥2.45M. The average tenure of the management team and the board of directors is 2.1 years and 3.4 years respectively.
Key information
Deyong Wen
Chief executive officer
CN¥10.0m
Total compensation
| CEO salary percentage | 25.9% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.004% |
| Management average tenure | 2.1yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
There May Be Some Bright Spots In Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Earnings
Nov 05
Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year
Aug 03Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden
Jul 28Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)
May 23Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
May 01We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings
Apr 02Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?
Mar 18Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?
Feb 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CN¥2b |
| Jun 30 2024 | n/a | n/a | CN¥2b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥10m | CN¥3m | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥8m | CN¥2m | CN¥4b |
Compensation vs Market: Deyong's total compensation ($USD1.38M) is above average for companies of similar size in the CN market ($USD265.96K).
Compensation vs Earnings: Deyong's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Deyong Wen (53 yo)
2.8yrs
Tenure
CN¥9,997,000
Compensation
Mr. Deyong Wen serves as Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since August 10 2022. He has been a Non-Executive Director at Shanghai Henlius Biotech, Inc. since July 28, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Co-Chairman | 2.9yrs | CN¥15.25m | 0.012% CN¥ 7.7m | |
| Executive Chairman | 8.3yrs | CN¥12.14m | 0.045% CN¥ 28.6m | |
| Joint President | 2.8yrs | CN¥10.00m | 0.0039% CN¥ 2.4m | |
| Executive Vice Chairman | 2.9yrs | CN¥9.14m | 0.011% CN¥ 7.0m | |
| Executive President & Chief Human Resources Office | less than a year | no data | 0.0043% CN¥ 2.7m | |
| Executive President and CEO of Established Medicines Manufacturing & Supply Division | no data | no data | 0.0043% CN¥ 2.7m | |
| Executive President | 1.8yrs | no data | no data | |
| Executive President & Co-CEO of Innovative Drug Division | 1.8yrs | no data | no data | |
| Senior VP & CFO | less than a year | no data | no data | |
| Director of the Accounting Department | no data | no data | no data | |
| Senior Vice President & Director of Pharmaceutical Commerce Admin Station Committee | 3.7yrs | no data | 0.0025% CN¥ 1.6m | |
| Senior VP & Chief Strategic Enabler | 4.1yrs | no data | 0.0043% CN¥ 2.7m |
2.1yrs
Average Tenure
55yo
Average Age
Experienced Management: 600196's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Co-Chairman | 2.9yrs | CN¥15.25m | 0.012% CN¥ 7.7m | |
| Executive Chairman | 8.3yrs | CN¥12.14m | 0.045% CN¥ 28.6m | |
| Joint President | 2.3yrs | CN¥10.00m | 0.0039% CN¥ 2.4m | |
| Executive Vice Chairman | 2.9yrs | CN¥9.14m | 0.011% CN¥ 7.0m | |
| Independent Non-Executive Director | 5.4yrs | CN¥392.00k | no data | |
| Non-Executive Director | 19.5yrs | no data | 0.0043% CN¥ 2.7m | |
| Non-Executive Director | 5.4yrs | no data | no data | |
| Independent Non-Executive Director | 5.4yrs | CN¥392.00k | no data | |
| Independent Non-Executive Director | 3.4yrs | CN¥392.00k | no data | |
| Non-Executive Director | less than a year | no data | 0.0058% CN¥ 3.6m | |
| Independent Non-Executive Director | 3.4yrs | CN¥392.00k | no data | |
| Chief Supervisor | 1.4yrs | no data | no data |
3.4yrs
Average Tenure
54yo
Average Age
Experienced Board: 600196's board of directors are considered experienced (3.4 years average tenure).